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Abstract 
The current model for breast cancer progression proposes independent “low-grade (LG) like” 
and “high-grade (HG) like” pathways but lacks a known precursor to HG cancer. We applied 
low coverage whole genome sequencing to atypical ductal hyperplasia (ADH) with and 
without carcinoma to shed light on breast cancer progression. 14/20 isolated ADH cases 
harboured at least one copy number alteration (CNA), but had fewer aberrations than LG or 
HG ductal carcinoma in situ (DCIS). ADH carried more HG-like CNA than LG DCIS (eg. 8q 
gain). Correspondingly, 64% (7/11) of ADH cases with synchronous HG carcinoma were 
clonally related, similar to LG carcinoma (67%, 6/9). This study represents a significant shift 
in our understanding of breast cancer progression, with ADH as a common precursor lesion 
to the independent “low-grade like” and “high-grade like” pathways. These data suggest that 
ADH can be a precursor of HG breast cancer and that LG and HG carcinomas can evolve 
from a similar ancestor lesion. We propose that although LG DCIS may be committed to a 
LG molecular pathway, ADH may remain multipotent, progressing to either LG or HG 
carcinoma. This multipotent nature suggests that some ADH could be more clinically 
significant than LG DCIS, requiring biomarkers for personalising management.  
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Introduction  
The current model for breast cancer progression proposes independent “low-grade like” and 
“high-grade like” pathways [1] where low-grade (LG) and high-grade (HG) invasive ductal 
carcinoma (IDC) progress from LG and HG ductal carcinoma in situ (DCIS), respectively 
[1,2]. Atypical ductal hyperplasia (ADH) is a common lesion associated with up to a 30% 
life-time risk of metachronous breast cancer [3,4]. ADH occurs within terminal ductal lobular 
units (TDLU) and appears as a proliferation of evenly spaced monomorphic epithelial cells 
that have well defined cell borders and generally rounded nuclei. The cells form “punched 
out” (cribriform-like) secondary lumens and/or micropapillae [5,6]. It is diagnostically 
challenging, lacking reproducibility across pathologists. ADH has been considered to be a 
general risk indicator, but a precursor for the LG pathway only, and thus, also of ER+ 
carcinoma only [1,2]. However, the genomic data was at odds with clinical observations that 
two-thirds of the cancers arising after a diagnosis of ADH are HG or intermediate grade (IG) 
[7,8]. Whether HG, HER2+ or ER- carcinoma could also develop from this lesion remains 
unclear.  
While some studies have identified a few common genomic features of ADH, a clear 
understanding of the molecular changes associated with ADH development has been limited 
by inadequately powered studies and/or low-resolution methodology [9–16].  
Copy number alteration (CNA) is the dominant somatic genetic event in breast cancer [1,17], 
and we previously used CNA to show that most DCIS is clonally related to co-existing IDC, 
validating DCIS as a direct precursor of IDC [18–20]. We hypothesised that a similar 
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analysis of ADH would provide an insight into early clonal expansions and clarify whether it 
can be a precursor of HG breast cancer. We carried out CNA analysis using low-coverage 
whole genome sequencing (LCWGS) of cases of ADH without carcinoma (pure ADH) and 
ADH with co-existing carcinoma of different grades. Because of the difficulties in diagnosing 
ADH, we consistently applied a strict histopathological definition in selecting the cohort. 
Methods  
Tumour samples  
All cases of ADH without carcinoma (pure ADH) and ADH co-existing with carcinoma 
(synchronous ADH) were identified from the Royal Melbourne Hospital (RMH) database 
from 1995 – 2015 with follow up until 2017 through the Victorian Cancer Registry. Cases 
were considered pure ADH when no carcinoma was reported in the 2–22 years preceding 
diagnosis (supplementary material, Table S1) as well as no carcinoma diagnosed within a 
year after ADH diagnosis. ADH from RMH were diagnosed by multiple pathologists with 
different levels of expertise, therefore, diagnostic haematoxylin and eosin (H&E) stained 
tissue sections of ADH (n=100) and synchronous ADH (n=40) were reviewed by a specialist 
breast anatomical pathologist PH. The criteria for ADH was according to Page et al. [6] and 
Lakhani et al. [5]: ADH is characterised by a proliferation within TDLU of a monomorphic 
population of epithelial cells with generally rounded nuclei that are evenly spaced and have 
well defined cell borders. The cells form “punched out” (cribriform-like) secondary lumens 
and/or micropapillae. The cells may grow in arcades or rigid bridges of uniform thickness 
(supplementary material, Figure S1). In distinguishing ADH from LG DCIS, the latter 
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required complete involvement of >2 ducts or partial involvement of ducts >2 mm in extent. 
Exclusion criteria were absence of atypical cells (i.e. usual ductal hyperplasia or UDH) 
(Figure S1), columnar cell change with UDH, and other early neoplasia with atypia such as 
flat epithelial atypia (FEA), radial scar or apocrine hyperplasia. Upon review, 40/100 pure 
ADH did not meet these criteria and were excluded, while 20/100 were considered LG DCIS 
and also excluded. Details of patient selection are shown in supplementary material, Figure 
S2.    
ADH with synchronous carcinoma was confirmed on review in 30/40 cases. Cases were 
excluded when the “ADH” was deemed to be a part of the associated carcinoma 
(supplementary material, Figure S3). We placed any cases with features of IG carcinomas 
into the LG group if LG carcinoma was also present (e.g. LG DCIS with G2 IDC) and IG 
cases with HG carcinoma into the HG group. Two cases with solely IG carcinoma were 
arbitrarily allocated to the HG group prior to data analysis  (supplementary material, Table S2 
and Supplementary materials and methods).  
Genomic data for LG DCIS cases (n=10) and HG DCIS cases (n=38) were derived from our 
previously published work [20,21], with new data from an additional 11 LG DCIS cases from 
the RMH, Peter MacCallum Cancer Centre and Nottingham University Hospitals NHS Trust, 
UK.  
This study was conducted under ethical approval from the Peter MacCallum Cancer Centre 
(HREC #12-64), Melbourne Health (HREC# 2012.119) and the North West-Greater 
Manchester Central Research Ethics Committee 15/NW/0685. 
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Tissue microdissection and DNA extraction  
Neoplastic epithelial cells were micro-dissected from 8-10 micron H&E stained sections (15-
20 per case) using the Roche Automated Tissue Dissection System to achieve >50% tumour 
purity. A new reference H&E slide was evaluated by pathologist JMP before dissection. 
Micro-dissected tissue was placed in buffer ATL and sonicated using the Covaris LE220 
system, followed by proteinase K digest. DNA was extracted using the MagAttract® HMW 
DNA miniKit (Qiagen, Hilden, Germany) as described [22] except for four LG DCIS cases 
that were extracted using the All Prep Kit (Qiagen).  
 
 
NEBNext® Ultra TM II DNA library preparation and low coverage whole-genome 
sequencing (LCWGS) 
Low DNA input library preparation was performed with the NEBNext® UltraTMII DNA 
Library Prep Kit (New England BioLabs® Inc., Ipswich, MA, USA) and used for LCWGS as 
previously [22]. An Illumina Nextseq500 (paired-end 75 bp reads) was used to run the 
pooled, normalized, indexed libraries according to the Illumina protocol. Sequencing depth 
ranged from 0.76–3.34x. (supplementary material, Table S3).  
Data analysis 
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Reads were aligned with bwa mem (v0.7.12-r1039) to hg19 after removal of sequencing 
primers by cutadapt (v1.7.1) as previously [22]. ControlFREEC (v6.7) [23] was used to 
estimate CN using 50 kb windows as described previously [22].  
Data were imported into Nexus (v8, BioDiscovery Inc., Hawthorne, CA, USA) and 
segmented using SNP-FASST. CNA were called if the log2 ratio was ±0.15. Blacklisted 
regions identified by Scheinin et al. [24] were filtered out as described previously [22]. FGA 
was calculated as described in supplementary material, Supplementary materials and 
methods.. 
CN segments were imported into Partek Genome Suite (Partek Inc., St. Louis, MO, USA) to 
perform unsupervised hierarchical clustering using Pearson dissimilarity and average linkage.  
Lesions were classified as clonally related when sharing e2 CNA with visually inspected 
shared breakpoints (supplementary material, Figures S4–S7) at 50 kb resolution, except one 
case where ADH and LG DCIS shared one rare CNA, gain of whole chromosome 8. The 
“Clonality” package (R v3.5.1) [25–28] was also used to test clonality. Averaging of data was 
carried out to reduce the data resolution to 15,000 markers as recommended [25].    
 
Statistical analysis  
GraphPad Prism v7 (GraphPad, Inc., San Diego, CA, USA) was used to generate graphs and 
perform statistical tests as indicated. A p value of <0.05 was considered significant. 
Results 
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Pure ADH show genetic characteristics of both low and high grade carcinoma 
Pure ADH diagnoses (n=20) were re-confirmed by extensive pathology review by PH, 
including of the subsequent excision for those ADH cases diagnosed on core biopsies to re-
confirm those lesions were not part of any LG DCIS (supplementary material, Table S1). All 
ADH were ER+ and CK5/6- (supplementary material, Figure S1). The median follow-up 
time was 6 years (2–22 years) with no patients recording a subsequent carcinoma in that 
period. CN profiling showed that 70% of pure ADH had at least one CNA with a median 
number of three events and a median fraction of the genome altered (FGA) of 5% (0–19%) 
(Figure 1). The most prevalent CN changes were 16q loss (65%), followed by 16p gain 
(35%), 1q gain (25%) and 8q gain (20%) (Table 1). 
We compared the spectrum and frequency of CNA in pure ADH with data from LG DCIS 
(n=21), HG DCIS (n=38) [20,21] and LG (grade 1) and HG (grade 3) IDC (METABRIC) 
[29]. LG and HG carcinoma (both DCIS and IDC) differ markedly in their CN profiles with 
81% of LG carcinomas harbouring 16q loss compared with 32% for HG cases (Figure 1D, 
Table 1). In pure ADH, the CN profiles resemble those of LG breast cancers with respect to 
16q loss (13/20 cases, 65%) (Table 1), but were less likely to have concomitant 1q gain 
(4/20) than LG DCIS (10/21 with 1q+/16q-), more resembling HG DCIS (9/38). 
Furthermore, some pure ADH cases showed a HG-like CN profile, with 8q gain (20%) or 20q 
gain (10%) (Table 1, Figure 1D). Partial or whole arm gain of 8q was more frequently 
observed in HG carcinoma (58% HG DCIS, 53% G3 IDC) compared with LG carcinoma 
cases (0% LG DCIS, 15% G1 IDC) (LG versus HG DCIS: p<0.0001, Fisher Exact test). 
There was a statistically significant difference observed between ADH and LG DCIS for 8q 
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gain (ADH 4/20 case, LG DCIS 0/21; p=0.04, Fisher’s Exact test). The HG-like CN profile 
of ADH was not limited to 8q gain, indeed 7/20 ADH cases carried CN events statistically 
significantly enriched in HG versus LG DCIS, such as 20q gain, 17p loss or 18q loss (Figure 
1A). Collectively, from these observations we hypothesised that ADH has the potential to 
progress directly to either LG or HG cancer.  
ADH is clonal to both low and high grade carcinoma 
We then investigated the clonal relationship of ADH co-existing with breast carcinoma of 
different grades. These ADH were defined based on their morphological appearance and 
cases were excluded if ADH was thought to be part of the carcinoma (supplementary 
material, Figure S3D, Table S1). We generated CN profiles for 20 such ADH cases and the 
synchronous ipsilateral carcinoma components (supplementary material, Table S1). Overall, 
65% of ADH was found to be clonal with the synchronous DCIS and/or IDC. The rate of 
clonality was not significantly different for synchronous LG (6/9 cases) and synchronous HG 
(7/11 cases) carcinoma (p>0.99, Figure 2A). This result was not substantially different if 
cases with IG carcinoma were considered separately (supplementary material, Table S2): 
clonality rates were 4/6 for purely LG carcinomas, 6/8 for carcinomas with any IG/G2 
component, and 3/6 for purely HG carcinomas. There was no difference observed for the size 
of the synchronous carcinoma (mean size clonal = 14.9 mm, non-clonal = 18.7 mm, p=0.93) 
or whether the ADH was located in the same or different tissue block (p=0.16, Figure 2B). 
When we compared the frequency of CNA (Figure 2C, 2D), non-clonal ADH cases showed 
almost no CNA and had an FGA no different to pure ADH (p=0.60), whereas clonal ADH 
had a significantly higher FGA than pure ADH (p=0.003).  
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Additionally, for one presumed non-clonal ADH case where no aberrations were identified 
by LCWGS (S12), we performed high coverage WGS (~25x) (supplementary material, 
Supplementary materials and methods) which confirmed the absence of shared somatic 
mutations or structural aberrations, further supporting an independent origin of the ADH and 
HG DCIS components.  
To summarise the clonal relationships, we performed unsupervised hierarchical clustering 
analysis (Figure 2E, supplementary material, Figure S8), which showed that 10/13 clonal 
cases clustered together with their associated carcinoma components. The same ten cases 
were also called clonal by the R package Clonality (supplementary material, Table S4). 
Although the three non-clustering cases (S13, S14, S4) shared CNA between ADH and 
carcinoma components, the latter carried two to three times as many additional CNA as 
shared events which may explain the lack of apparent clonal relationship. However, they 
shared multiple breakpoints at a fine resolution, which is highly unlikely to be due to chance 
and suggestive of true clonal events that might be underestimated by a statistical approach 
(Figure S6, S7). Both the clustering and Clonality approaches evaluate the balance of CNA, 
and consider multiple additional events to be indicative of a distant or no relationship. In pre-
malignant breast lesions, shared breakpoints should be emphasized more strongly as 
suggested previously [26,30], since carcinomas carry a significantly higher burden of CNA, 
which is not taken into account by Clonality.  
Pure ADH lack some CNA frequent in breast carcinoma 
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Despite sharing some CNA at similar frequency to carcinomas, other regions of the genome 
were only rarely observed to be altered in ADH (Table 1). Striking differences were observed 
for gain of chromosomes 17q and 21q as well as loss of chromosome X, none of which were 
detected in pure ADH but were common in DCIS (Table 1, Figure 1D). Similarly, 11q loss, 
11q13.1–11q13.4 high gain, 13q loss, 17p loss and 22q loss were more frequent in DCIS 
compared with pure ADH (single case each) (Table 1, Figure 1D). Overall, the absence or 
low frequencies of these CNA in pure ADH but common occurrence in DCIS suggest that 
these are potential genetic drivers of progression from ADH to DCIS.  
Additionally, loss of chromosome 14 or 15 was not observed in ADH nor in LG DCIS, but 
were frequent events in HG DCIS (14q: 43.2%; 15q: 32.4%) and HG IDC (Figure 1D), 
suggestive of events specific to HG carcinoma. Certain CNA on chromosomes 3, 5, 7, 10 and 
18 were also specific to HG carcinoma, although with low frequencies (supplementary 
material, Table S5). Interestingly, 8q gain and 20q gain were mutually exclusive in pure 
ADH cases (Figure 1A); however, 26% cases of HG DCIS showed both 8q gain and 20q 
gain, indicating that these could be major co-occurring CNA driving HG DCIS. HG DCIS 
cases lacking 8q gain (42%) were more likely to have ERBB2 amplification along with 20q 
gain (supplementary material, Figure S9). The remainder carried multiple losses of either 
13q, 14q, 15q, 18, 17p along with 20q gain (supplementary material, Figure S9). Thus, to 
progress from ADH, combinations of 8q gain and/or 20q gain with other CNA appear to be 
required for HG carcinoma development, which is distinct from the LG pathway (e.g. 13q 
loss was enriched: 1/21 cases for LG DCIS versus13/38 for HG DCIS, p=0.02, Fisher’s Exact 
test).  
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Overall, statistically significantly lower CNA frequencies were observed in pure ADH 
(median FGA 5%) compared to LG DCIS (p=0.04), HG DCIS and IDC (both p<0.0001) 
(Figure 1C). Collectively, these data are consistent with ADH being a genetically less 
advanced lesion compared to carcinomas.  
Genetic events associated with malignant progression from ADH  
Clonal ADH harboured specific CNA reflective of those characteristic for the synchronous 
cancer grade (Table 1), for example, ADH adjacent to HG carcinoma commonly harboured 
>2 CN events (6/7) (Figure 1B), including frequent HG-like events such as 8p loss with 8q 
gain, or 20q gain accompanied by other CNA specific to HG carcinoma such as in 
chromosomes 13 and 17 (Figure 3). Loss of 11q was significantly more common in clonal 
ADH compared to pure ADH (5/13 cases versus 1/20, p=0.02) and other events were 
recurrently observed in clonal ADH but absent from pure ADH (X loss, 17q gain) or rare in 
pure ADH (13q loss, 22q loss, 17p loss, 11q13.1–q13.4 high gain) (Table 1).  
If clonal ADH represents the less advanced precursor of the synchronous carcinoma, we 
might expect the carcinoma to contain additional genetic events that promoted progression. 
Indeed, for 10/13 clonal cases the associated carcinoma had at least one additional CNA. 
Some of these additional events were seen in multiple cases, for example, 7q gain was seen 
only in the carcinoma components (n=4, e.g. Figure 3A). Of note, two clonal ADH cases 
carried CNA absent from the carcinoma suggesting that one subclone of the ADH kept 
evolving without developing into carcinoma, while another progressed.  
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Although most of the synchronous carcinomas were ER+, both the ER- case (S17) (Figure 4) 
and the ER+/ERBB2 amplified case (S13) (both HG) were clonal with the co-existing ADH. 
Intriguingly, the ADH component of the latter had gain but not high-level amplification of 
ERBB2 (Figure 5) with multiple additional gains and amplifications in the HG DCIS across 
chromosome 17. This profile suggests that low-level gain of ERBB2 may be an early event, 
but high-level amplification accompanied the progression to carcinoma. In addition, the CN 
profiles indicate a highly divergent pattern of evolution whereby the ADH component 
analysed may have branched off from the clone that evolved into carcinoma at an early phase 
in the neoplastic expansion, while sharing the same shared breakpoint at chromosome 16q 
(supplementary material, Figure S6). 
 
 
Discussion 
ADH has previously been thought to be a precursor to LG carcinoma only [10-16] based 
predominantly on the absence of evidence for shared loss of heterozygosity between 
synchronous ADH with HG cases, and that more than 70% of LG DCIS and ADH showed 
16q loss [1]. However, this conclusion has been based on limited data from low resolution 
technology. An expression microarray study found that ADH showed a LG gene expression 
signature and clustered well with LG DCIS/IDC, although with just 7 carcinomas, 5 of which 
were LG [31]. The exclusion of a precursor relationship between ADH and HG breast cancer 
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was mostly driven by lack of data rather than explicit data excluding this possibility. 
Consequently, this led to one theory that HG carcinoma developed “de novo” [1].  
The key limitation of previous studies is their very small sample sizes (average n=6) [10–
16,32–34] often due to a large DNA input requirement, which itself leads to a potential 
sample selection bias, i.e. restricted to larger ADH. A further limitation has been the lack of 
objective and definitive criteria for diagnosis of ADH and limited pathological review of the 
cases. It is likely that some studies have potentially included other types of early neoplasia 
misdiagnosed as ADH such as FEA or columnar cell hyperplasia, included parts of associated 
LG DCIS rather than pure lesions or even included residual normal tissue following depletion 
of ADH cells after diagnostic sectioning [33,34]. Consequently, the conclusions drawn by 
comparing genetic features may be compromised.  
In the current study we have overcome previous limitations by combining improved genomic 
analysis technology with stringent selection and expert pathological review of ADH to 
explore the molecular landscape and malignant potential of ADH. The high drop-out rate on 
review of cases previously diagnosed as ADH (60% of cases were reclassified as not ADH, 
supplementary material, Figure S2) indicates the necessity of our exacting approach.  
To our knowledge, our study is the first to demonstrate that a subset of ADH can directly 
progress to HG carcinoma including ER- or ERBB2 amplified. A clonality study by Larson et 
al [13] did not clearly state the grades of carcinoma, but it is likely that at least two ADH in 
their cohort were clonal to HG carcinoma. The genetic events accompanying clonal 
expansion from ADH to HG DCIS varied from case to case in our cohort. For example, we 
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found that gain of 8q (including the MYC locus) preceded development of carcinoma in two 
cases, but was a later event in others. Two other synchronous cases showed 20q gain 
(including ZNF217 at 20q13.2) instead of 8q gain, along with other CN events specific to HG 
carcinoma (Figure 3C). Data from some previous studies are consistent with our findings, for 
example 8q gain was reported in two studies of pure ADH; albeit with caveats on sample size 
(n=2) [16] and data quality [10]. A CGH study of synchronous ADH with IG/HG IDC 
showed both 8q gain and 20q gain for 2 out of 3 ADH [32]. It is important to remember that 
there are inconsistent data available for both pure and synchronous ADH with many 
limitations in previous studies to consider. 
It is well documented that tumours recurring after a diagnosis of DCIS are usually the same 
grade as the original diagnosis [5,35]; whereas carcinomas diagnosed after an ADH can be of 
any grade [8]. These studies are in keeping with our data, suggesting that once DCIS has 
developed it is committed to that molecular pathway, while ADH remains multipotent with 
respect to progressing to low or high grade, ER+ or ER-, HER2+ or HER2- carcinoma. In 
other words, our data demonstrates that the model of breast cancer progression with 
independent “low-grade like” and “high-grade like” pathways could include ADH as a 
common precursor lesion for any grade. Additionally, our observation that ADH but not LG 
DCIS can have sub-chromosomal 8q gain may explain why LG DCIS rarely recurs as HG 
carcinoma, since the latter is characterised by this event (>75% HG cases shown by others) 
[1]. The absence of sub-chromosomal 8q gain in LG DCIS was also observed by others [36–
40]. We speculate that ADH with such changes could be clinically more significant than LG 
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DCIS; the 10-year recurrence rates are similar (10–15%), but more ADH have the genomic 
potential to progress to the clinically more aggressive HG carcinoma.   
Our cohort had only one ERBB2 amplified DCIS and one ER- IDC case, both of which 
carried a clonal ADH (itself ERBB2 unamplified/ER+). We found that the ERBB2 amplified 
DCIS had amplification of ERBB2 unlike the ADH component of this case (Figure 5). One 
existing FISH study supports our data whereby low-level CN gain was present in the ADH 
component of the synchronous cases and high-level amplification in the carcinoma [41]. 
These data support ADH as a precursor for ER+/ERBB2 amplified cases, but as yet it is 
unknown whether ADH could precede ER-/HER2+ carcinoma, a very aggressive and fast-
growing entity that could overgrow any co-existing ADH. A small subset of tumours 
occurring after ADH diagnosis were HER2+ (7%) and ER- (9%) [8], lower than rates in 
carcinoma overall [42] yet potentially supporting our finding that ADH could be clonal to 
some ER- disease and not only ER+ carcinoma, despite their fundamental differences [1]. 
This proportion is consistent with the 10% of IDC with synchronous ADH that were ER- 
[43]. We only had one case of ADH synchronous with ER-/HER2- IDC (clonal), and the 
genomic profile included CN characteristics of ER- carcinoma, such as 5p gain and 10p gain 
(Figure 4) [29]. Thus, more cases are required to determine the precursor relationship of 
ADH with ER- carcinoma, as no other study has targeted this group. As ER-/HER2- IDC are 
associated with BRCA1 mutations, it would be worth investigating if this potential precursor 
relationship is observed in mutation carriers, patients with family history and/or younger 
patients.   
This article is protected by copyright. All rights reserved.
  
 
A substantial proportion of ADH were shown to be non-clonal, implying a possible field 
cancerisation effect [44]. Indeed, Page and Dupont [6] found that cancer developing in the 
ipsilateral breast after ADH diagnosis could occur in a different quadrant of the breast and 
thus possibly non-clonal, unlike most DCIS recurrences [20]. However, due to the 
unavailability of somatic mutation data, we cannot be completely certain that the non-clonal 
cases are truly non-clonal, which would lead to an underestimation of the clonality rate. 
The increase in CNA, both globally and of particular loci, from ADH to LG and HG 
carcinoma indicates that these could be later events in breast cancer progression. Indeed, 
clonal ADH cases were enriched with similar CNA, suggesting they provide a selective 
advantage for one of the cancer hallmarks [45] either by amplifying regions of oncogenes, 
such as CCND1 (11q13.1–13.4 gain), or loss of tumour suppressor genes, such as RB1 (13q 
loss). Although with small sample size, some previous studies also found 11q loss [9,13], or 
13q loss [9,32] to be more common in synchronous ADH, and more changes in chromosome 
17 in pure DCIS than pure ADH [9]. Moreover, in keeping with previous studies [13,32], 
most associated carcinoma components showed additional CNA than the synchronous clonal 
ADH, collectively suggesting that ADH represents the first clonal expansion of breast 
cancerized lineages and that additional genetic changes are required to proceed to DCIS and 
invasive disease of any grade. This model is consistent with other evolutionary studies 
showing that advanced malignancies tend to have more genetic changes than early tumours 
[46].   
In conclusion, our study is the largest whole-genome study of ADH to date and shows that it 
has potential to develop into LG and HG breast carcinoma, including ER- and HER2+ 
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subtypes. It was previously inexplicable why later development of the tumours after ADH 
diagnosis were often of HG/IG given the prevailing dogma that ADH could only progress to 
LG cancer. Our data suggests a model of breast cancer progression (Figure 6) that includes 
ADH as a multipotent precursor with different initiating CNA steering progression to either 
LG or HG carcinoma. This suggests that CN analysis of ADH biopsies could be used in the 
clinical setting to personalize management by identifying which subset of patients are at 
higher risk of developing cancer, and in particular the clinically more aggressive HG 
carcinoma. Future studies using ADH cases with extensive follow up are required to compare 
the molecular profiles of cases that subsequently developed cancer or not. Such a study might 
enable us to distinguish the cancerized lineages [47] from the non-cancerized lineages 
whereby the former, in an appropriate micro-environmental context, will drive cancer 
progression from ADH.    
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 Table 1. Genetic features in pure ADH, pure LG DCIS, pure HG DCIS and clonal ADH 
 Number of cases (%) Number of cases (%) P value 
Major and common 
CNA of pure ADH 
Pure ADH 
(n=20) 
Pure LG DCIS 
(n=21) 
Pure HG DCIS 
(n=38) 
Clonal ADH (n=13) grades of 
associated carcinoma 
Pure ADH 
versus Clonal 
ADH 
16q loss 13/20 (65%) 17/21 (80.9%) 12/38 (31.6%) 10/13 (76.9%) 5 HG, 5 LG 0.7 
1q gain 
 
5/20 (25%) 10/21 (47.6%) 19/38 (50%) 6/13 (46.2%) 3 HG, 3 LG 0.27 
16q loss and 1q gain 
 
4/20 (20%) 10/21 (47.6%) 9/38 (23.7%) 6/13 (46.2%) 3 HG, 3 LG 0.14 
Cases with 1q gain also 
with 16q loss 
4/5 (80%) 10/10 (100%) 9/19 (47.4%) 6/6 (100%) 50% LG, 50% HG 0.45 
16p gain 
7/20 (35%) 7/21 (33.3%) 9/38 (23.7%) 2/13 (15.4%) both HG 0.26 
16p gain and 16q loss 
7/20 (35%) 7/21 (33.3%) 6/38 (15.8%) 2/13 (15.4%) both HG 0.26 
8q gain 4/20 (20%); 3/20 0 22/38 (57.9%) 4/13 (30.8%) 3 HG (8q gain), 0.68 
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full arm; 1/20 
8q22.2-24.22 
1WC 8 gain LG 
8p loss and 8q gain 
3/20 (15%) 0 14/38 (36.8) 3/13 (23.1%) all HG 0.66 
20q gain 
 
2/20 (10%) 
WC 20 1/21 
(4.8%); 20q13.2 (7 
Mb) 1/21; 
Total 2/21 (9.5%) 
19/38 (50%) 2/13 (15.4%) both HG 1 
20p loss and 20q gain 2/20 (10%) 0 2/38 (5.3%) 0 0.5 
17q loss  
2/20 (10%) 
(1/20: 17q12-
25.3); 1/20: 
17q11.2-21.32, 
17q24.2-25.3) 
2/21 (9.5%) 3/38 (7.9%) 1/13 (7.7%) LG 1 
CNA associated with 
progression to 
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carcinoma 
11q loss 1/20 (5%) 5/21 (23.8%) 15/38 (39.5%) 5/13 (38.5%) 2 LG, 3 HG 0.02 
13q loss 1/20 (5%) 1/21 (4.8%) 13/38 (34.2%) 3/13 (23.1%) 2 LG, 1 HG 0.28 
13q gain 0 0 5/38 (13.2%) 1/13 (7.7%) LG 0.4 
22q loss 1/20 (5%) 4/21 (19%) 8/38 (21.1%) 3/13 (23.1%) 2 HG, 1 LG 0.27 
X loss 0 4/21 (19%) 8/38 (21.1%) 2/13 (15.4%) both HG 0.15 
X gain 
1/20 (5%) 
(Xq11.1-21.1) 
4/21 (19%) 3/38 (7.9%) 1/13 (7.7%) LG 1 
11q13.1-q13.4 high 
gain 
1/20 (5%) 4/21 (19%) 10/38 (26.3%) 2/13(15.4%) 1 HG, 1 LG 0.55 
17p loss 1/20 (5%) 3/21 (14.3%) 23/38(60.5%) 2/13 (15.4%) both HG 0.54 
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17q gain 0 4/21 (19%) 18/38 (47.4%) 2/13 (15.4%) both HG 0.14 
21q gain 0 1/21 (4.8%) 12/38 (31.5%) 0 1 
  P value from Fisher’s Exact test (significant P values are in bold). WC: Whole chromosome; CNA: copy number alterations. All CNA indicate full arm gain/loss 
unless specified.   
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Figure 1. CN analysis of pure ADH and comparison to carcinoma. (A) CNA profile of 20 
pure ADH Top: Overall frequency of CNA with chromosome number above. Bottom: 
Individual sample profiles (P1-P20). Blue = gain; red= loss. CNA <1 Mb have been filtered 
out to reduce background noise and sequence artefacts. (B) Proportion of cases with different 
numbers of CN events observed in pure ADH, DCIS, clonal ADH with LG cancer, clonal 
ADH with HG cancer and non-clonal ADH cases. (C) Fraction of the genome altered by CN; 
mean ± standard deviation. Unpaired t-test with Welch’s correction was used for statistical 
analysis; *p<0.05, ****p<0.0001. D. Frequency plots of CN gain (blue) and loss (red) with 
chromosome number on top; comparing pure ADH with synchronous ADH and carcinoma 
(IDC cases from METABRIC). CNA <1 Mb have been filtered out to reduce background 
noise and sequence artefacts for ADH and LG DCIS cases.  
Figure 2. Clonality of ADH. (A) Number of clonal/non-clonal cases comparing grades of 
carcinoma. Fisher’s Exact test was performed. (B) Number of the clonal/non-clonal cases 
based on whether they are in the same/different block. (C) Comparison of FGA; mean ± SD. 
Mann–Whitney two-tailed test; ** p<0.01, ns; not significant. (D) Overall frequency plots of 
CN gain (blue) and loss (red). (E) Unsupervised hierarchical clustering of clonal and non-
clonal ADH cases with carcinoma based on CNA segments. Left: the sample ID and the 
component of the cases (ADH=A/DCIS=D/IDC=I) with colour codes; ADH/A=pink, 
DCIS/D=green, IDC/I=red; the grades of DCIS/IDC: low grade=1, intermediate=2, high 
grade=3. Row dendrogram coloured by individual sample ID regardless of the components 
(ADH/DCIS/IDC) (i.e. 1 case=1 colour). X-axis: Chromosome number on top; bottom: CN 
ratio: blue=loss, red=gain. Clonal ADH cases clustered together (n=10) marked with black 
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asterisks and the remaining 3 clonal ADH cases marked with black hashtag. A larger version 
of this Figure is available as supplementary material, Figure S8.   
Figure 3. Genetic progression of ADH to carcinoma.(A). Typical clonal ADH/HG 
carcinoma case with gain of chromosome 7 in the DCIS and IDC components and further 
gain of chromosome 8 in the G3 IDC only. (B) Clonal ADH case with LG carcinoma: CN 
profiles are identical without additional changes in carcinoma. (C) Clonal ADH case with HG 
carcinoma where 20q gain along with other CNA preceded the development of carcinoma 
with additional 18q loss only for carcinoma components. (D) Clonal ADH case with IG 
carcinoma showing shared 8q gain. (A-D, CN gain in blue and loss in red).  
Figure 4. Clonal ADH case with ER negative IDC (S17). The top panel shows two ADH 
foci which were clonal with ER-ve IDC. ADH are shown with their matched CK5/6 (-ve) and 
ER immunostaining images(+ve). This ADH was in a different block and was separated from 
the tumour site. ER immunostaining is shown for the G3 IDC component (-ve). The bottom 
panel shows genome-wide copy number profiles: ADH and IDC components shared gain of 
5p and 10p as well as Xq loss with additional events for carcinoma components. Red 
indicates loss and blue indicates gain.  
Figure 5. Clonal ADH case with ERBB2 amplified HG DCIS (S13). The top panel shows 
H&E images for synchronous ADH foci (ERBB2 unamplified) and ERBB2 amplified HG 
DCIS. Genome-wide copy number profile of these two components showed shared events 
such as 8q gain, 16q loss, and 17p loss, as well as additional events in the DCIS component. 
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The bottom panel shows chromosome 17 of both ADH and HG DCIS components. Red 
indicates loss and blue indicates gain. Red arrow indicates the region of ERBB2.  
Figure 6. Revised breast cancer progression model including ADH as a common 
precursor for both LG and HG carcinoma. An unknown event in normal ductal epithelium 
produces a diploid tumour-initiating cell (46 chromosomes) with a growth advantage that 
evolves to become ADH. This ADH might have no CNA and is unable to initiate tumorigenic 
clonal expansion, remaining as ADH (“evolutionary dead end”). CNA like 16q loss or 
concomitant 16q loss and 1q gain might be the initiating event for ADH to progress towards 
the LG pathway. Once ADH has started along this pathway, limited other CNA such as 11q 
loss, 11q13.1 high gain and/or 22q loss are the most likely to accompany progression. On the 
other hand, a subset of ADH harbouring 8q gain could directly progress to the HG pathway. 
ADH could also harbour or accumulate other HG specific CNA such as 20q gain, 13q loss, 
17q gain, 17p loss and progress to HG carcinoma. The order of these secondary events may 
not be crucial. Our model incorporates data from other studies showing that LG and HG IDC 
have progressed from LG and HG DCIS, respectively. We have focussed on CNA because 
our data identifies only these events, however, we recognise that individual gene mutations 
will also be important in this process. 
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SUPPLEMENTARY MATERIAL ONLINE  
Supplementary materials and methods  Yes 
Supplementary figure legends  NO, because legends are embedded with their figures 
Figure S1. Representation of pure ADH cases which were re-confirmed or excluded from the 
initial ADH database. 
Figure S2. Patient selection. 
Figure S3. Representation of ADH cases synchronous with different grades of carcinoma 
either re-confirmed or excluded after review. 
Figure S4. Examples of shared break points of clonal ADH samples shown in Figure 3C,D. 
Figure S5. Examples of shared break points of clonal and non-clonal ADH samples. 
Figure S6. Examples of shared break points of two clonal ADH cases that showed 
discordance using the R Clonality package. 
Figure S7. Examples of genome wide copy number profile and shared break points of clonal 
ADH case (S4) that showed discordance using the R Clonality package. 
Figure S8. Correlation plots.  
Figure S8. Unsupervised hierarchical clustering of clonal and non-clonal ADH cases with 
carcinoma based on CNA segments (larger version of Figure 2E) 
Figure S9. Correlation plot 
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Table S1. Sample information 
Table S2. Characteristics of synchronous ADH cases 
Table S3. Sequence performance and DNA input 
Table S4. Summary of clonal relatedness of ADH cases 
Table S5. Other CNA of pure ADH 
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